MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Page standards status: Informative |
{
"resourceType" : "PlanDefinition",
"id" : "RegimenDdACT",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/anticancer-regimen-plandefinition"
]
},
"language" : "en",
"text" : {
"status" : "extensions",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n <table class=\"narrative-table\">\n <tbody>\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">Metadata</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">ddAC→T: Dose-Dense Doxorubicin/Cyclophosphamide then Paclitaxel — Breast Cancer</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Version</th>\n\n\n\n<td class=\"content-container\">0.1.1-snapshot-080926</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Experimental</th>\n\n\n\n<td class=\"content-container\">true</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Subject Type</th>\n\n\n\n<td class=\"content-container\">\n Malignant neoplasm of breast\n\n\n</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Jurisdiction</th>\n\n\n\n<td class=\"content-container\">\n United States of America\n\n\n</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Steward (Publisher)</th>\n\n\n\n<td class=\"content-container\">HL7 International / Clinical Interoperability Council</td>\n\n\n</tr>\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Steward Contact</th>\n\n\n\n<td class=\"content-container\">HL7 International / Clinical Interoperability Council</td>\n\n\n</tr>\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Description</th>\n\n\n\n<td class=\"content-container\"><div><p>Dose-dense AC x4 cycles (q14d) with pegfilgrastim support, followed by paclitaxel x4 cycles (q14d) for breast cancer.</p>\n</div></td>\n\n\n</tr>\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Type</th>\n\n\n\n<td class=\"content-container\">\n Order Set\n\n\n</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">ac-phase</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">AC Phase — Doxorubicin + Cyclophosphamide (q14d × 4 cycles)</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Count 4 times, Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action (Parent Action ID: ac-phase)</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">doxorubicin-ac</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Doxorubicin 60 mg/m² IV — Day 1 of each 14-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">doxorubicin-ac</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Doxorubicin 60 mg/m² IV — Day 1 of each 14-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action (Parent Action ID: ac-phase)</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">pegfilgrastim-ac</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Pegfilgrastim 6 mg subcutaneous — Day 2 of each 14-day cycle</td>\n\n\n</tr>\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Description</th>\n\n\n\n<td class=\"content-container\">Pegfilgrastim supportive care on day 2 of each ddAC cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">pegfilgrastim-ac</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Pegfilgrastim 6 mg subcutaneous — Day 2 of each 14-day cycle</td>\n\n\n</tr>\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Description</th>\n\n\n\n<td class=\"content-container\">Pegfilgrastim supportive care on day 2 of each ddAC cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action (Parent Action ID: ac-phase)</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">cyclophosphamide-ac</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Cyclophosphamide 600 mg/m² IV — Day 1 of each 14-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">cyclophosphamide-ac</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Cyclophosphamide 600 mg/m² IV — Day 1 of each 14-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n\n\n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">t-phase</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">T Phase — Paclitaxel (q14d × 4 cycles)</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Count 4 times, Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action (Parent Action ID: t-phase)</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">paclitaxel-t</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Paclitaxel 175 mg/m² IV — Day 1 of each 14-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n \n<tr>\n\n\n<th colspan=\"2\" scope=\"row\" class=\"row-header\">PlanDefinition Sub-Action</th>\n\n\n</tr>\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Id</th>\n\n\n\n<td class=\"content-container\">paclitaxel-t</td>\n\n\n</tr>\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Title</th>\n\n\n\n<td class=\"content-container\">Paclitaxel 175 mg/m² IV — Day 1 of each 14-day cycle</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n\n<tr>\n\n\n<th scope=\"row\" class=\"row-header\">Timing</th>\n\n\n\n<td class=\"content-container\">Once per 14 days</td>\n\n\n</tr>\n\n\n\n\n\n\n\n\n\n\n\n\n \n \n\n\n\n\n\n<tr>\n <th colspan=\"2\" scope=\"row\" class=\"row-header\">Generated using version 0.5.4 of the sample-content-ig Liquid templates</th>\n</tr>\n\n </tbody>\n </table>\n</div>"
},
"url" : "http://hl7.org/fhir/us/codex-mopa/PlanDefinition/RegimenDdACT",
"version" : "0.1.1-snapshot-080926",
"name" : "RegimenDdACT",
"title" : "ddAC→T: Dose-Dense Doxorubicin/Cyclophosphamide then Paclitaxel — Breast Cancer",
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/plan-definition-type",
"code" : "order-set",
"display" : "Order Set"
}
]
},
"status" : "active",
"experimental" : true,
"subjectCodeableConcept" : {
"coding" : [
{
"system" : "http://snomed.info/sct",
"code" : "254837009",
"display" : "Malignant neoplasm of breast"
}
]
},
"date" : "2026-09-08T18:17:28-04:00",
"publisher" : "HL7 International / Clinical Interoperability Council",
"contact" : [
{
"name" : "HL7 International / Clinical Interoperability Council",
"telecom" : [
{
"system" : "url",
"value" : "http://www.hl7.org/Special/committees/cic"
},
{
"system" : "email",
"value" : "ciclist@lists.HL7.org"
}
]
}
],
"description" : "Dose-dense AC x4 cycles (q14d) with pegfilgrastim support, followed by paclitaxel x4 cycles (q14d) for breast cancer.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "US",
"display" : "United States of America"
}
]
}
],
"action" : [
{
"id" : "ac-phase",
"title" : "AC Phase — Doxorubicin + Cyclophosphamide (q14d × 4 cycles)",
"timingTiming" : {
"repeat" : {
"count" : 4,
"period" : 14,
"periodUnit" : "d"
}
},
"action" : [
{
"id" : "doxorubicin-ac",
"title" : "Doxorubicin 60 mg/m² IV — Day 1 of each 14-day cycle",
"timingTiming" : {
"repeat" : {
"period" : 14,
"periodUnit" : "d"
}
}
},
{
"id" : "pegfilgrastim-ac",
"title" : "Pegfilgrastim 6 mg subcutaneous — Day 2 of each 14-day cycle",
"description" : "Pegfilgrastim supportive care on day 2 of each ddAC cycle",
"timingTiming" : {
"extension" : [
{
"extension" : [
{
"url" : "day",
"valueInteger" : 2
}
],
"url" : "http://hl7.org/fhir/us/codex-mopa/StructureDefinition/regimen-days-of-cycle"
}
],
"repeat" : {
"period" : 14,
"periodUnit" : "d"
}
}
},
{
"id" : "cyclophosphamide-ac",
"title" : "Cyclophosphamide 600 mg/m² IV — Day 1 of each 14-day cycle",
"timingTiming" : {
"repeat" : {
"period" : 14,
"periodUnit" : "d"
}
}
}
]
},
{
"id" : "t-phase",
"title" : "T Phase — Paclitaxel (q14d × 4 cycles)",
"relatedAction" : [
{
"actionId" : "ac-phase",
"relationship" : "after-end"
}
],
"timingTiming" : {
"repeat" : {
"count" : 4,
"period" : 14,
"periodUnit" : "d"
}
},
"action" : [
{
"id" : "paclitaxel-t",
"title" : "Paclitaxel 175 mg/m² IV — Day 1 of each 14-day cycle",
"timingTiming" : {
"repeat" : {
"period" : 14,
"periodUnit" : "d"
}
}
}
]
}
]
}